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Background: Obesity causes metabolic disease and is a serious health problem around the world.
Polygonum cuspidatum (POCU1b) has been used clinically for the treatment of constipation, gallstones, hepatitis,
and inflammation in East Asian countries. The principal aim of this study was to investigate for the first time
whether the extract of Polygonum cuspidatum (POCU) biologically affects adipogenesis in 3 T3-L1 preadipocytes.
Methods: Fractions (n-hexan, ethyl acetate, n-butanol, and water) of POCU ethanol extract were evaluated in vitro
for their inhibitory activities on pancreatic lipase. Of the fractions, the n-butanol of POCU ethanol extract (POCU1b)
was examined anti-obesity activity in 3 T3-L1 preadipocytes. To examine the inhibitory effect of POCU1b on
adipogenesis, 3 T3-L1 preadipocytes were treated every the other day with POCU1b at various concentrations
(0 ~ 25 μg/mL) for twelve days. Oil-red O staining and triglyceride content assay were performed to determine the
lipid accumulation. The expression of mRNA and proteins associated lipid accumulation was measured using
RT-PCR and Western blotting analysis. We also examined the effect of POCU1b on level of phosphorylated
AMP-activated protein kinase (pAMPK) in 3 T3-L1 preadipocytes with POCU1b at various concentrations during
adipocyte differentiation.
Results: POCU1b exhibited the most pronounced inhibitory effects on pancreatic lipase activity. We found that
POCU1b inhibited adipocyte differentiation in 3 T3-L1 preadipocytes in a dose-dependent manner, as evidenced by
the reduced formation of lipid droplets and decreased glycerol-3-phosphate dehydrogenase (GPDH) activity. We
also showed that the expression levels of adipocyte differentiation-related protein (ADRP) and perilipin (a protein
that coats lipid droplets in adipocytes) were both reduced after POCU1b treatment. Peroxisome proliferator-
activated receptor-gamma (PPAR-γ) and CCAAT/enhancer-binding protein-alpha (C/EBP-α) proteins, both major
adipogenic transcription factors, were markedly reduced by POCU1b. Moreover, ADRP, perilipin, C/EBP-α, and
PPAR-γ mRNA levels were also reduced by POCU1b. Levels of phosphorylated AMP-activated protein kinase
(pAMPK) were elevated after POCU1b treatment (5, 10, and 25) in a dose-dependent manner.
Conclusions: Taken together, these results suggest that the anti-obesity effects of POCU1b involve the inhibition of
pancreatic lipase activity and adipogenesis via the down-regulation of lipid accumulation.
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Obesity, a common nutritional disorder, results from the
disequilibrium between energy intake and expenditure. It
is believed to be associated with numerous diseases, in-
cluding hyperlipidemia, hypercholesterolemia, hyperten-
sion, and type 2 diabetes [1,2]. Adipocytes store excess
energy in the form of triglycerides which are contained
inside lipid droplets, organelles composed of a neutral
lipid core surrounded by a protein-coated single
phospholipid layer [3]. Both the number and size of
mature adipocytes are increased compared with preadi-
pocytes in adipose tissues, and the inhibition of adipo-
genesis during the maturation of preadipocytes to
adipocytes regulates the amount of adipose tissue mass
[4].
Natural products have the potential to inhibit adi-
pogenesis and induce the apoptosis of mature adipo-
cytes [5,6]. Herbal extracts and phytochemicals have
shown anti-obesity effects, especially the down-
regulation of the adipogenic transcriptional factors
peroxisome proliferator-activated receptor-γ (PPAR-γ)
and CCAAT/enhancer binding protein-α (C/EBP-α),
the inhibition of fatty acid accumulation, and the
stimulation of glycerol-3-phosphate dehydrogenase
(GPDH) activity in 3 T3-L1 preadipocytes [7-10].
Berberine, a natural plant product, displays beneficial
effects in the treatment of diabetes and obesity at
least in part via the stimulation of AMP-activated
protein kinase (AMPK) activity [11]. AMPK is an
intracellular energy sensor that plays a central role in
the regulation of lipid and glucose metabolism [12].
Hydroxycitric acid (HCA), the active ingredient in
the herbal compound Garcinia cambogia, acts as an
anti-obesity agent and has been used as a natural
supplement for weight management [13]. Recently,
newer approaches for the treatment of obesity have
involved inhibition of dietary triglyceride absorption
via inhibition of pancreatic lipase as this is the major
source of excess calories [14]. Orlistat is the deriva-
tive of lipstatin, a potent natural inhibitor of pancre-
atic lipases isolated from bacterium. Orlistat promotes
body weight loss and reduces the incidence of dia-
betes by nearly 40% in obese people [15]. However, it
has serious side effects, such as steatorrhea, stomach
pain, irregular menstrual periods, and headaches [16].
Polygonum cuspidatum (P. cuspidatum, Polygonaceae)
has been used clinically for the treatment of consti-
pation, gallstones, hepatitis, and inflammation in
East Asian countries such as Korea, China, Taiwan,
and Japan [17], little work has been carried out re-
garding the effects on anti-obesity. In the present
study, to elucidate activities of P. cuspidatum on
anti-obesity, we screened candidates for lipase inhibi-
tory activity from the P. cuspidatum fractions andinvestigated the effects of butanol fraction of the
ethanol extract of P. cuspidatum (POCU1b) on the
regulation of adipocyte differentiation. Our findings
suggest for the first time that POCU1b inhibits adi-
pocyte differentiation through the attenuation of
lipid accumulation.
Methods
Preparation of Polygonum cuspidatum extract
Radix of P. cuspidatum were purchased from a com-
mercial supplier in Jung-dong, Daejeon, Korea in
November 2008 and identified by Prof. J.H. Kim in
the Department of Life Science, Gachon University.
A voucher specimen was deposited at the Herbarium
of Diabetic Complication Research Team, Korea
Institute of Oriental Medicine. The dried plant ma-
terial (5.5 kg) was extracted with ethanol (3 × 36 L)
by maceration at room temperature for 3 days and
the extracts were concentrated in vacuo at 40°C.
The concentrated extract (580 g) was diluted in
water (2 L) and then partitioned successively with
n-hexane, ethyl acetate, n-butanol, and water, re-
spectively. The percentage (w/w) yield of the lyophi-
lized butanol fraction of the ethanol extract of
P. cuspidatum (POCU1b) was 1.9%. For water ex-
tract, the dried plant (0.1 kg) was extracted with boiling
water (3 × 1.5 L) and the extract was in vacuo at 40°C.
The percentage yield of water extract was 24.8%.
Pancreatic lipase activity of Polygonum cuspidatum
extract and its fractions
The method for measuring pancreatic lipase activity was
modified from that of Kim and colleagues [18,19].
Briefly, an enzyme buffer was prepared by the addition
of a solution of porcine pancreatic lipase [2.5 mg/ml in
10 mM MOPS (morpholinepropanesulphonic acid) and
1 mM EDTA, pH 6.8] to 169 μl of Tris buffer (100 mM
Tris-HC1 and 5 mM CaCl2, pH 7.0). Then, either 20 μl
of the plant extracts and fractions at the test concentra-
tion, or orlistat, was mixed with 20 μl of the enzyme buf-
fer and incubated for 15 min at 37°C with 5 μl of the
substrate solution [10 mM p-NPB (p-nitrophenyl butyr-
ate) in dimethyl formamide]. The enzymatic reactions
were allowed to proceed for 30 min at 37°C. Lipase ac-
tivity was determined by measuring the hydrolysis of
p-NPB to p-nitrophenol at 405 nm using an ELISA
reader (BIO-TEK, Synergy HT, VT, USA).
Culture and differentiation
The 3 T3-L1 preadipocyte cell line was purchased from
the American Type Culture Collection (Rockville, MD,
USA). The cells were cultured in 4.5 g/L glucose-
DMEM with 10% calf serum, penicillin (100 U/ml), and
streptomycin (100 μg/ml) in 10-cm plastic Petri dishes
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2-day post-confluent cells were incubated for 48 h in
DMEM with 10% FBS, antibiotics, and a differentiation
cocktail termed MDI, which contained 0.5 mM isobutyl-
methylxanthine, 1 μM dexamethasone, and 1 μg/ml in-
sulin. After 48 h, the cells were maintained in DMEM
with 10% FBS, antibiotics, and 5 μg/ml insulin. Cells
were cultured for 12 days in DMEM with 10% FBS and
antibiotics, and the media changed every 2 days until the
cells were collected for analysis.
Cytotoxicity assay
Cytotoxicity was evaluated in vitro by determining cell
viability using the CCK-8 kit (Cell Counting Kit-8,
Dojindo laboratories, Tokyo, Japan). Cells were plated at
a density of 1 × 103 cells/ml in 96-well plates and
allowed to attach overnight. The cells were then treated
with POCU1b (1–200 μg/ml) and incubated for 5 and
12 days. After a 4-h incubation with the CCK-8 solution,
absorbance was measured with a microtiter plate reader
(Bio-Tek, Winooski, VT, USA) at 450 nm. We calculated
the percent viability as optical density of treated sample/
optical density of untreated control × 100.
Oil Red O staining for intracellular triglycerides
Cells were washed twice with PBS on day 12 and fixed
on dishes with 3% formaldehyde in PBS for 20 min.
After two rinses with PBS, cells were incubated with an
Oil red O solution (0.5% Oil red O, 60% isopropanol,
and 40% water) and filtered through a 0.22-μm filter for
30 min. The monolayer was extensively washed with
water to remove unbound dye. Representative images of
treated cells were obtained with an Olympus microscope
(BX51, Japan), equipped with an Olympus DP 70 cam-
era. Stained cells were air-dried overnight and then dis-
solved in isopropanol. Absorbance was measured at
520 nm.
Glycerol-3-phosphate dehydrogenase (GPDH) activity
assay
Treated cell lysates were extracted and used to deter-
mine GPDH activity as described [20,21]. Briefly, protein
lysate was measured according to the bicinchoninic acid
assay (BCA) method, and the GPDH assay was per-
formed to assess the disappearance of NADH during the
GPDH-catalyzed reduction of dihydroxyactone phos-
phate (DHAP) under zero-order conditions as described
[20,21].
Immunoblotting
Immunoblotting was performed using a previously de-
scribed method [22]. Cells were homogenized in a solution
containing 250 mM sucrose, 1 mM ethylenediaminetetra-
acetic acid (EDTA), 0.1 mM phenylmethylsulfonyl fluoride(PMSF), and 20 mM potassium phosphate buffer (pH 7.6).
Equal amounts of protein (25–50 μg/lane) were subjected
to immunoblotting with the indicated antibodies. The
antibodies used were the following; PPAR-γ (1:1000),
adipocyte differentiation-related protein (ADRP, 1:1000),
perilipin (1:1,000) from Santa Cruz Biotechnology (Santa
Cruz, CA, USA); pAMPK, and C/EBP-α (1:1,000) from
Cell Signaling (MA, USA). The bound horseradish
peroxidase-conjugated secondary antibody was detected
using an enhanced chemiluminescence detection system
(iNtRON Biotechnology, SeongNam-Si, Korea). Protein
expression levels were determined by analyzing the signals
captured on the nitrocellulose membranes using an image
analyzer (Las-3000, Fuji photo,Tokyo, Japan).RNA extraction and semi-quantitative RT-PCR
Total RNA isolation and RT-PCR were performed as
previously described [22]. For RT-PCR, cDNA was syn-
thesized with 1 μg RNA using RT-premix (Bioneer,
Daejeon, Korea). The primers used are summarized in
Table 1. QuantumRNA 18S (Ambion Inc., Austin, TX,
USA) was used as an internal control. PCR products
were analyzed by agarose (1.2%) gel electrophoresis
along with DNA molecular markers, stained with
ethidium bromide, and visualized under UV light. The
intensities of RT-PCR products in the agarose gels were
quantified by densitometry (Las-3000, Fuji photo).Statistical analysis
Data are expressed as the mean ± S.E.M. from multiple
experiments. Comparison between groups was per-
formed using a one-way ANOVA followed by a Tukey’s
test (PRISM software, Graph Pad, San Diego, CA, USA).Results
Lipase inhibitory activity of Polygonum cuspidatum
extract and fractions
First, we evaluated in vitro the lipase inhibitory activity
of natural products and P. cuspidatum was chosen for
more detail investigation. Pancreatic lipase inhibition of
P. cuspidatum extract and fractions is expressed as per-
centage and IC50 (Table 2). Butanol fraction of the etha-
nol extract of P. cuspidatum (POCU1b) exhibited the
strongest inhibitory effect on lipase with an IC50 value of
15.8 μg/ml. Next, we tested the effect of P. cuspidatum
extract and fractions on adipocyte differentiation of
3 T3-L1 preadipocytes. POCU1b was the most effective
in the prevention of adipogenesis (Additional file 1:
Figure S1). Thus, we investigated the anti-obesity effects
of POCU1b on adipocyte differentiation of 3 T3-L1 pre-
adipocytes and the related molecular mechanism of lipid
accumulation.
Table 1 Sequences of primers and PCR conditions for semi-quantitative RT-PCR
Gene Sequence (5′-3′) Annealing temperature (°C) Size (bp) Accession No.
ADRP 55 352 NM_00748
Sense CTT GTG TCC TCC GCT TAT GTC AGT
Anti-sense CTG CTC CTT TGG TCT TAT CCA CCA
Perilipin 55 508 NM_175640
Sense CTT TCT CGA CAC ACC ATG GAA ACC
Anti-sense CCA CGT TAT CCG TAA CAC CCT TCA
PPAR-γ 55 220 NM_011146
Sense CCA GAG CAT GGT GGG TTC GCT G
Anti-sense GAG CTG ACC CAA TGG TTG CTG
C/EBP-α 55 238 NM_007678
Sense AGG TGG TGG AGT TGA CCA GT
Anti-sense CAG CCT AGA GAT CCA GCG AC
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Cytotoxicity assay was performed to evaluate whether
POCU1b had any effects on 3 T3-L1 viability and to de-
termine the optimal conditions required. During the dif-
ferentiation processes, 3 T3-L1 preadipocytes were treated
with insulin and POCU1b for 5 and 12 days (Figure 1A).
There were no effects on cytotoxicity at low concentra-
tions of POCU1b (1, 5, 10, and 25 μg/ml) and HCA
(25 μg/ml) (Figure 1B). However, high concentrations of
POCU1b (100 and 200 μg/ml) altered cell viability afterTable 2 Lipase inhibitory activity of Polygonum cuspidatum fr
Scientific name Fraction





a Results are the mean ± S.E.M. (n = 3).12 days (Figure 1C). Hydroxycitric acid (HCA, a positive
anti-obesity control) did not alter cytotoxicity after 12 days
at concentrations up to 50 μg/ml.
POCU1b inhibits adipocyte differentiation and GPDH
activity
To determine the effects of POCU1b on adipogenic con-
version, 3 T3-L1 preadipocytes were induced to differen-
tiate in the presence or absence of POCU1b and stained
with Oil red O. Lipid droplets in untreated control cellsactions
Conc. (μg/ml) Inhibition (%)a IC50 (μg/ml)
0 0 ± 4.8 72.5 ± 6.7
50 45.8 ± 1.9
100 54.9 ± 0.3
150 62.7 ± 3.2
0 0 ± 4.8 326.9 ± 36.6
200 33.9 ± 3.2
300 44.7 ± 7.3
400 64.1 ± 7.2
0 0 ± 4.8 26.4 ± 1.9
20 44.6 ± 3.4
30 52.5 ± 0.7
40 54.1 ± 0.4
0 0 ± 4.8 15.8 ± 2.6
10 46.5 ± 0.3
15 49.7 ± 2.4
20 52.8 ± 1.4
0 0 ± 4.8 295.8 ± 10.9
200 46.6 ± 1.6
300 50.1 ± 0.2
400 52.8 ± 0.6
Figure 1 Cytotoxicity of POCU1b. (A) 3 T3-L1 differentiation. (B) Cytotoxicity of POCU1b using the CCK-8 kit. Cells were treated with different
concentrations of POCU1b for 5 or 12 days. Data are expression as the mean ± S.E.M. (n = 4). (C) Cytotoxicity at high concentrations of POCU1b.
Cells were treated with high concentrations of POCU1b (~200 μg/mL) for 12 days. Data are expression as the mean ± S.E.M. (n = 6).*p < 0.05,
**p < 0.01 vs. untreated cells.
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the cells accumulated substantial amounts of cytoplas-
mic triglycerides. Representative images of Oil red O
staining in treated cells showed that POCU1b sup-
pressed both triglyceride accumulation and adipocyte
differentiation in a dose-dependent manner (Figure 2A
and 2B). HCA treatment of cells also reduced staining
with Oil red O, indicative of low triglyceride content.
Expression of GPDH is induced the conversion of pre-
adipocytes to adipocytes [23]. We examined the effect of
POCU1b on the activity of GPDH. POCU1b treatment
of 3 T3-L1 adipocytes resulted in a marked decrease in
GPDH activity in a dose-dependent manner (Figure 2C;
POCU1b 25 μg/ml vs. control, p < 0.05).POCU1b phosphorylates AMP-activated protein kinase
(AMPK)
Several studies have suggested that AMPK acts as a
major energy sensor and regulator in adipose tissues
[24] and that activation of AMPK leads to lipid low-
ering [25]. To determine the effects of POCU1b on
AMPK activation in 3 T3-L1 adipocytes, cells were
treated with or without POCU1b and AMPK was de-
tected by immunoblot analysis. Levels of pAMPK
were markedly increased in a dose-dependent manner
following POCU1b treatment (Figure 3). At a same
dose (25 μg/ml), these resulted in a 78% increase for
POCU1b and 17% increase for HCA.Effect of POCU1b on expression of lipid accumulation-
related factors
ADRP stimulates lipid accumulation and lipid drop-
let formation [26]. Therefore, we tested the effects of
POCU1b on the expression of ADRP, a lipid-associated
protein that is expressed during early adipose differenti-
ation. POCU1b reduced protein and mRNA expression
levels of ADRP in a dose-dependent manner (Figure 4).
Similar to ADRP, perilipin stimulated lipid accumulation
and localized to the surfaces of lipid droplets [27,28]. As
shown in Figure 4, perilipin protein (Figure 4A, middle
panel) and mRNA (Figure 4B, middle panel) expression
levels decreased in POCU1b-treated 3 T3-L1 adipocytes
in a dose-dependent manner.Effect of POCU1b on mRNA and protein expression levels
of adipogenic factors
To determine whether suppression of both triglycer-
ide accumulation and GPDH activity was caused by
the inhibition of an adipogenic mechanism, we exam-
ined the expression levels of mRNA and protein of
the adipogenic transcription factors PPAR-γ and C/
EBP-α in POCU1b-treated 3 T3-L1 adipocytes. As
shown in Figure 5, POCU1b reduced both protein
(Figure 5A, upper panel) and mRNA (Figure 5B,
upper panel) expression levels of PPAR-γ compared
with standard differentiated adipocytes in a dose-
dependent manner. Both protein and mRNA expression
Figure 2 POCU1b inhibits adipocyte differentiation and GPDH activity. (A) Oil red O staining for lipid content in 3 T3-L1 adipocytes. 3 T3-L1
preadipocytes were induced to differentiate in POCU1b (5–25 μg/mL) for 12 days. (B) Relative density of Oil red O staining. Data are expressed as
the mean ± S.E.M. (n = 5). **p < 0.01, and ***p < 0.001 vs. untreated cells, respectively. (C) Confluent 3 T3-L1 preadipocytes were induced to
differentiate in the presence or absence of POCU1b (5, 15, or 25 μg/mL). Cells were lysed on day 12, and GPDH activity was measured. Data are
expressed as means ± S.E.M. (n = 5) for three independent experiments, normalized to GPDH activity obtained under standard differentiation
conditions. ***p < 0.001 vs. untreated cells.
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dependent manner in POCU1b-treated 3 T3-L1 cells
(Figure 5A and B, middle panel). Thus, we conclude that
POCU1b regulates the production of adipogenic tran-
scription factors during the adipocyte differentiation
process in 3 T3-L1 adipocytes.Figure 3 POCU1b activates AMPK signaling in a dose-dependent man
determined by immunoblot analysis. Data represent the mean ± S.E.M. of a
and ***p < 0.001 vs. untreated cells, respectively.Discussion
In the present study, POCU1b exhibited the strongest
inhibitory effect on lipase activity and the putative anti-
obesity effects of POCU1b were investigated for the first
time through the inhibition of adipocyte differentiation.
POCU1b suppressed triglyceride accumulation in 3 T3-L1ner. Cells were collected after 12 days and lysed. AMPK activation was
t least three experiments performed in triplicate. *p < 0.05, **p < 0.01,
Figure 4 Effects of POCU1b on expression of ADRP and perilipin expression levels. (A) ADRP and perilipin protein levels were detected by
immunoblot analysis and suppressed in a dose-dependent manner by POCU1b. Data represent the mean ± SEM of at least three experiments
performed in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. untreated cells, respectively. (B) Expressions of ADRP and perilipin mRNA were
analyzed by RT-PCR and suppressed in a dose-dependent manner by POCU1b. Data represent the mean ± S.E.M. of at least three experiments
performed in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. untreated cells, respectively.
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differentiation) was also significantly diminished by
POCU1b in a dose-dependent manner, and pAMPK activ-
ity was markedly increased in 3 T3-L1 adipocytes. Fur-
thermore, both ADRP and perilipin levels were decreased,
and levels of the adipogenic transcription factors PPAR-γ
and C/EBP-α were also significantly decreased after
POCU1b treatment. We also observed reduced lipidcontent in adipocytes, increased phosphorylation of
AMPK, inhibition of lipid accumulation via lower ADRP
and perilipin levels, and the inhibition of differentiation in
3 T3-L1 adipocytes.
Natural products have been commonly used as dietary
supplements to control body weight [13,14]. P. cuspida-
tum has also been used as a natural laxative in trad-
itional Asian herbal medicines [17]. In our study, the
Figure 5 Effects of POCU1b PPAR-γ and C/EBP-α on protein and mRNA expression levels. (A) PPAR-γ and C/EBP-α protein levels were
detected by immunoblot analysis and suppressed in a dose-dependent manner by POCU1b. Data represent the mean ± SEM of at least three
experiments performed in triplicate. *p < 0.05 and **p < 0.01 vs. untreated cells, respectively. (B) Expressions of PPAR-γ and C/EBP-α mRNA were
analyzed by RT-PCR. Data represent the mean ± SEM of at least three experiments performed in triplicate. *p < 0.05, **p < 0.01, and ***p < 0.001
vs. untreated cells, respectively.
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lipase activity, with an IC50 value of 72.5 ±67 μg/ml.
Especially, POCU1b showed the strongest activity
(IC50 = 15.8 ± 1.9 μg/ml). P. cuspidatum is composed of
phytochemicals such as emodin and resveratrol
[17,29,30]. The anti-diabetic effects of emodin and res-
veratrol have been studied both in vitro and in vivo
[12,31,32]. A recent study showed that emodin exhibits
a very high-binding affinity to PPAR-γ and induces botha time- and dose-dependent increase in glucose uptake
as well as in GLUT1 and GLUT4 mRNA expression
levels in differentiated 3 T3-L1 adipocytes [33].
Adipocytes play a critical role in the regulation of en-
ergy balance. Adipose tissue growth involves an increase
in adipocyte size and/or number. Changes in adipocyte
number are achieved through a complex interplay be-
tween the proliferation and differentiation of preadipo-
cytes. Adipocyte differentiation (adipogenesis) regulates
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this study, POCU1b inhibited adipocyte differentiation in
3 T3-L1 cells in a dose-dependent manner. It is note-
worthy that inhibition of adipocyte differentiation reduces
adipocyte number in WAT, which acts as a secretory/
endocrine organ that mediates numerous physiological
and pathological processes.
GPDH activity is high in mature adipocytes; the activ-
ity of this enzyme is therefore routinely measured to as-
sess adipogenic differentiation in cultured cells [35] and
has been used as an index for monitoring triglyceride
synthesis [21]. In the current study, we found that treat-
ment with POCU1b (25 μg/ml) suppressed GPDH activ-
ity without affecting cell viability. However, treatment
with HCA, an active compound of Garcinia cambogia,
had no significant effects on cells after 12 days (Data not
shown). Hasegawa et al. showed consistently that GPDH
activity was not significantly inhibited by treatment with
Garcinia extract after 21 days. However, the accumula-
tion of lipid droplets was inhibited [36]. AMPK is acti-
vated when cellular energy stores are depleted and
accelerates ATP-generating catabolic pathways, includ-
ing glucose and fatty acid oxidation, while reducing
ATP-consuming anabolic pathways, including fatty acid
and triacylglycerol synthesis [12]. POCU1b activated
AMPK in a dose-dependent manner, suggesting that the
reduction in energy storage and the increase in energy
production occurred through a change in the intracellu-
lar ATP-to-AMP ratio (Figure 3).
Proteins on the surfaces of lipid droplets in adipocytes,
especially ADRP and perilipin, serve as nucleation cen-
ters for the assembly of lipids into nascent lipid droplets
[31,37]. Expression of ADRP and perilipin was also
inhibited by POCU1b treatment in 3 T3-L1 adipocytes.
POCU1b also blocked the expression of the adipogenic
transcription factors C/EBP-α and PPAR-γ, shown to be
important players in adipocyte differentiation. C/EBP-α
knock-out (C/EBPα −/−) mice neither develop adipose
tissue normally nor accumulate triglycerides, the hall-
mark of WAT, suggesting a central role for C/EBP-α in
adipogenesis [38]. Additionally, PPAR-γ is known to be a
key protein that is expressed prior to C/EBP-α expres-
sion during early adipocyte differentiation of 3 T3-L1
cells [39].
Conclusions
The present study demonstrated that POCU1b blocks
3 T3-L1 adipocyte differentiation in a dose-dependent
manner and inhibits the expression of the key transcrip-
tion factors PPAR-γ and C/EBP-α. This study also
showed that POCU1b treatment prevents the expression
of ADRP and perilipin by both attenuating lipid accumu-
lation and activating AMPK phosphorylation. Thus,
POCU1b is worthwhile to further investigate for itspotential pharmacological effect in metabolic disorders,
specifically obesity.
Additional file
Additional file 1: Figure S1. POCU1 inhibits adipocyte differentiation.
Oil red O staining for lipid content in 3 T3-L1 adipocytes. 3 T3-L1
preadipocytes were induced to differentiate in extract (25 μg/mL) or fractions
(25 μg/mL) for 12 days. POCU1, the ethanol extract of P. cuspidatum;
POCU1h, n-hexane fraction of the ethanol extract of P. cuspidatum; POCU1ea,
ethyl acetate fraction of the ethanol extract of P. cuspidatum; POCU1b,
n-butanol fraction of the ethanol extract of P. cuspidatum; POCU1w, Water
fraction of the ethanol extract of P. cuspidatum.
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